Harrow Health, Inc. (HROW)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Harrow Health, Inc. currently loses $24.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 9
in 60 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Harrow Health, Inc.
Harrow Health, Inc. (NASDAQ: HROW) is a healthcare company that develops and sells specialty ophthalmic pharmaceuticals and compounded medicines. Through its ImprimisRx brand and products such as DEXYCU, it serves eye-care needs including post-operative inflammation management, and it generated $272.3 million in FY2025 revenue.
Today's Snapshot
HROW opened 0.9% lower at 37.22, while its sector was flat.
Trading Volume
Below 10d avg (373.2K)
102.9K
vs S&P 500 Today
Underperforming Market
-1.99%
Updated: September 10, 2026 at 15:11 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$38.02 - $40.91Sell
- RSI (14)39.75Neutral
- Stochastic %K (14, 3, 3)17.32Buy
- MACD Level (12, 26)-0.77Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.